Introducing a New Concept for Value-Driven Acceleration in Biopharma Development
Using a minimum valuable product and process approach would make it is possible to discipline and structure the development of biopharmaceuticals in the fastest way possible.
Ipopba/Stock.adobe.com
This opinion paper seeks to introduce a disruptive model to accelerate product and process development in the biopharmaceutical industry, especially for vaccines. This model is based on the minimum valuable product and process (MVaP&P), a new concept that allows for adaptation and acceleration, which would enable agility in the way biopharmaceuticals are developed. This article discusses how the MVaP&P approach would make it is possible to discipline and structure biopharmaceutical development to achieve a phase-appropriate and strategy-aligned product in the fastest time possible.
Click here for a PDF of this article.Peer-reviewed research
Submitted: May 12, 2022
Article accepted: June 28, 2022
About the authors
Matthew Sanders* is vice-president, head of Global Drug Substance; Roland Mainil is director, Technical Development Lead; and Wael Chahim* is associate director, Development Unit Head; all at GSK, Rixensart, Belgium.
*Both authors contributed equally to this paper.
Article details
BioPharm International
Vol. 35, No. 10
October 2022
Pages: 34–41
Citation
When referring to this article, please cite it as M. Sanders, R. Mainil, and W. Chahim, “Introducing a New Concept for Value-Driven Acceleration in Biopharma Development,” BioPharm International 35 (10) 34–41 (2022).
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
